151 related articles for article (PubMed ID: 19170302)
21. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Devonshire VA; Feinstein A; Moriarty P
BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043
[TBL] [Abstract][Full Text] [Related]
22. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject.
Mohr DC; Boudewyn AC; Likosky W; Levine E; Goodkin DE
Ann Behav Med; 2001; 23(2):125-32. PubMed ID: 11394554
[TBL] [Abstract][Full Text] [Related]
23. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
24. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Lugaresi A; Florio C; Brescia-Morra V; Cottone S; Bellantonio P; Clerico M; Centonze D; Uccelli A; di Ioia M; De Luca G; Marcellusi A; Paolillo A;
BMC Neurol; 2012 Mar; 12():7. PubMed ID: 22390218
[TBL] [Abstract][Full Text] [Related]
25. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
[TBL] [Abstract][Full Text] [Related]
26. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
27. [Teaching intramuscular self-injection in patients with multiple sclerosis reaching interferon beta-1a: evaluation of a descriptive multicenter program].
Visy JM; Gentin M; Bazerque C;
Presse Med; 2007 Jun; 36(6 Pt 1):841-50. PubMed ID: 17482792
[TBL] [Abstract][Full Text] [Related]
28. MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.
Vallittu AM; Salmi AA; Erälinna JP;
Neurol Sci; 2006 Feb; 26(6):438-43. PubMed ID: 16601938
[TBL] [Abstract][Full Text] [Related]
29. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
[TBL] [Abstract][Full Text] [Related]
30. [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests].
Selmaj K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z
Neurol Neurochir Pol; 2003; 37(6):1163-83. PubMed ID: 15174231
[TBL] [Abstract][Full Text] [Related]
31. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
Kinkel RP; Simon JH; O'Connor P; Hyde R; Pace A
Mult Scler Relat Disord; 2014 Nov; 3(6):712-9. PubMed ID: 25891550
[TBL] [Abstract][Full Text] [Related]
32. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
[TBL] [Abstract][Full Text] [Related]
33. Does drawing up technique influence patients' perception of pain at the injection site?
Rock D
Aust N Z J Ment Health Nurs; 2000 Sep; 9(3):147-51. PubMed ID: 11887258
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
[TBL] [Abstract][Full Text] [Related]
35. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a.
Zivadinov R; Zorzon M; Tommasi MA; Nasuelli D; Bernardi M; Monti-Bragadin L; Cazzato G
J Neurol Sci; 2003 Dec; 216(1):113-8. PubMed ID: 14607312
[TBL] [Abstract][Full Text] [Related]
36. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes.
McKay M; Compion G; Lytzen L
Diabetes Technol Ther; 2009 Mar; 11(3):195-201. PubMed ID: 19267582
[TBL] [Abstract][Full Text] [Related]
37. Interferon-beta injection site reactions in patients with multiple sclerosis.
Maurelli M; Bergamaschi R; Antonini A; Fargnoli MC; Puma E; Mallucci G; Totaro R; Girolomoni G
J Dermatolog Treat; 2018 Dec; 29(8):831-834. PubMed ID: 29671656
[TBL] [Abstract][Full Text] [Related]
38. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study.
Zecca C; Pavelek Z; Přikrylová K; Ghielmetti M; Beeler A; Gobbi C
Mult Scler Relat Disord; 2019 May; 30():104-109. PubMed ID: 30763907
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
[TBL] [Abstract][Full Text] [Related]
40. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6mm and Micro Fine Plus 31-gauge 5mm needles.
Iwanaga M; Kamoi K
Diabetes Technol Ther; 2009 Feb; 11(2):81-6. PubMed ID: 19848573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
